Ivey Business School (Canada)
-
Hoffmann-La Roche: Pricing the Zelboraf Melanoma Treatment for Canada
Mark Zbaracki; Jedy WangCase IVEY-9B16M138-EStrategyThe Canadian brand manager of Zelboraf had to decide how to introduce and price Zelboraf in the Canadian market. Zelboraf was a breakthrough discovery in treatment for melanoma cancer patients. Hoffmann-La Roche (Roche) began developing Zelboraf in 2005. During the clinical trials, the drug yielded such positive results in targeting late-stage (metastatic) melanoma cancer that Roche ended clinical trials early in order to expedite FDA approval an...Starting at €8.20